BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kami K, Fujita Y, Igarashi S, Koike S, Sugawara S, Ikeda S, Sato N, Ito M, Tanaka M, Tomita M, Soga T. Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations. Mitochondrion 2012;12:644-53. [PMID: 22884939 DOI: 10.1016/j.mito.2012.07.113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Fujita Y, Ito M, Kojima T, Yatsuga S, Koga Y, Tanaka M. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion 2015;20:34-42. [DOI: 10.1016/j.mito.2014.10.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
2 Nakada C, Hijiya N, Tsukamoto Y, Yano S, Kai T, Uchida T, Kimoto M, Takahashi M, Daa T, Matsuura K, Shin T, Mimata H, Moriyama M. A transgenic mouse expressing miR-210 in proximal tubule cells shows mitochondrial alteration: possible association of miR-210 with a shift in energy metabolism. J Pathol 2020;251:12-25. [PMID: 32073141 DOI: 10.1002/path.5394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Fujita Y, Ito M, Ohsawa I. Mitochondrial stress and GDF15 in the pathophysiology of sepsis. Arch Biochem Biophys 2020;696:108668. [PMID: 33188737 DOI: 10.1016/j.abb.2020.108668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Koga Y, Povalko N, Inoue E, Nashiki K, Tanaka M. Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease. Mitochondrion 2019;48:11-5. [PMID: 30738201 DOI: 10.1016/j.mito.2019.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
5 Li H, Uittenbogaard M, Hao L, Chiaramello A. Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics. Metabolites 2021;11:233. [PMID: 33920115 DOI: 10.3390/metabo11040233] [Reference Citation Analysis]
6 Fujii T, Nozaki F, Saito K, Hayashi A, Nishigaki Y, Murayama K, Tanaka M, Koga Y, Hiejima I, Kumada T. Efficacy of pyruvate therapy in patients with mitochondrial disease: a semi-quantitative clinical evaluation study. Mol Genet Metab 2014;112:133-8. [PMID: 24830361 DOI: 10.1016/j.ymgme.2014.04.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
7 Schaffer SW, Shimada-Takaura K, Jong CJ, Ito T, Takahashi K. Impaired energy metabolism of the taurine‑deficient heart. Amino Acids 2016;48:549-58. [PMID: 26475290 DOI: 10.1007/s00726-015-2110-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
8 Esterhuizen K, Lindeque JZ, Mason S, van der Westhuizen FH, Rodenburg RJ, de Laat P, Smeitink JAM, Janssen MCH, Louw R. One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation. Metabolomics 2021;17:10. [PMID: 33438095 DOI: 10.1007/s11306-020-01769-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ikawa M, Okazawa H, Nakamoto Y, Yoneda M. PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction. Antioxidants (Basel) 2020;9:E861. [PMID: 32937849 DOI: 10.3390/antiox9090861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ehinger JK, Piel S, Ford R, Karlsson M, Sjövall F, Frostner EÅ, Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, Elmér E. Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency. Nat Commun 2016;7:12317. [PMID: 27502960 DOI: 10.1038/ncomms12317] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
11 Esterhuizen K, van der Westhuizen FH, Louw R. Metabolomics of mitochondrial disease. Mitochondrion 2017;35:97-110. [DOI: 10.1016/j.mito.2017.05.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
12 Booth SC, Weljie AM, Turner RJ. Computational tools for the secondary analysis of metabolomics experiments. Comput Struct Biotechnol J 2013;4:e201301003. [PMID: 24688685 DOI: 10.5936/csbj.201301003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
13 Esterhuizen K, Lindeque JZ, Mason S, van der Westhuizen FH, Suomalainen A, Hakonen AH, Carroll CJ, Rodenburg RJ, de Laat PB, Janssen MC, Smeitink JA, Louw R. A urinary biosignature for mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS). Mitochondrion 2019;45:38-45. [DOI: 10.1016/j.mito.2018.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]